We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy.
US-headquartered gene therapy company Asklepios BioPharmaceutical has acquired Paris-based gene therapy company BrainVectis, a spin out from the French National Institute for Health and Medical Research.